Search alternatives:
greatest decrease » treatment decreased (Expand Search), greater increase (Expand Search)
largest decrease » larger decrease (Expand Search), marked decrease (Expand Search)
large decrease » larger decrease (Expand Search), marked decrease (Expand Search), large increases (Expand Search)
b large » _ large (Expand Search), a large (Expand Search), _ larger (Expand Search)
greatest decrease » treatment decreased (Expand Search), greater increase (Expand Search)
largest decrease » larger decrease (Expand Search), marked decrease (Expand Search)
large decrease » larger decrease (Expand Search), marked decrease (Expand Search), large increases (Expand Search)
b large » _ large (Expand Search), a large (Expand Search), _ larger (Expand Search)
-
201
-
202
-
203
Table 2_Hyper-fractionated radiotherapy as a bridging strategy to enhance CAR-T efficacy by regulating T-cell co-stimulatory molecules in relapsed/refractory diffuse large B-cell l...
Published 2024“…</p>Aims<p>This study aims to investigate the efficacy and safety of bridging hyper-fractionated radiotherapy in combination with CAR-T therapy for relapsed/refractory diffuse large B-cell lymphoma. The potential mechanisms were explored.…”
-
204
Table 1_Hyper-fractionated radiotherapy as a bridging strategy to enhance CAR-T efficacy by regulating T-cell co-stimulatory molecules in relapsed/refractory diffuse large B-cell l...
Published 2024“…</p>Aims<p>This study aims to investigate the efficacy and safety of bridging hyper-fractionated radiotherapy in combination with CAR-T therapy for relapsed/refractory diffuse large B-cell lymphoma. The potential mechanisms were explored.…”
-
205
Table 3_Hyper-fractionated radiotherapy as a bridging strategy to enhance CAR-T efficacy by regulating T-cell co-stimulatory molecules in relapsed/refractory diffuse large B-cell l...
Published 2024“…</p>Aims<p>This study aims to investigate the efficacy and safety of bridging hyper-fractionated radiotherapy in combination with CAR-T therapy for relapsed/refractory diffuse large B-cell lymphoma. The potential mechanisms were explored.…”
-
206
-
207
Effects of CGA on renal biochemical markers.
Published 2025“…<div><p>Diabetic nephropathy (DN) is the single largest cause of end-stage renal disease (ESRD). Inflammation reaction mediated by NLRP3 inflammasome and Nrf2-related oxidative stress have been considered to play a very important role in the progress of diabetic nephropathy (DN). …”
-
208
-
209
-
210
-
211
-
212
-
213
<b>Role of the Chaperone ClpB in</b><b> </b><b>Mycoplasma bovis</b><b> Virulence: Implications for </b><b>stress response, a</b><b>dhesion, </b><b>b</b><b>iofilm </b><b>d</b><b>eve...
Published 2025“…Despite its well-conserved function in prokaryotes, the specific contributions of ClpB to the pathogenesis of the ruminant pathogen Mycoplasma bovis remain largely unexplored. …”
-
214
-
215
Clinical diagnostic efficacy comparison of the proposed hybrid model and benchmark machine learning models. Metrics are reported as point estimates with 95% CIs. This table offers a discussion of the measures of high interest in clinical implementation. Sensitivity (true positive rate) reflects the ability to correctly identify patients with CVD, while Specificity (true negative rate) indicates the ability to correctly rule out patients without CVD. The Negative Likelihood Ratio quantifies how much the odds of having the disease decrease with a negative test result, where smaller values indicate stronger diagnostic power....
Published 2025“…The Negative Likelihood Ratio quantifies how much the odds of having the disease decrease with a negative test result, where smaller values indicate stronger diagnostic power. …”
-
216
Dox-inducible expression of HA-MAD1 in colon is sufficient to decrease p53 expression and cause chromosome missegregation.
Published 2024“…<p>(A-B) Immunofluorescence of colonic epithelium showing expression of HA (A) and increased expression of MAD1 (B) in HA-MAD1 animals after 1 week of 6 mg/kg dox feed. …”
-
217
-
218
-
219
-
220